Skip to main content
. 2022 Sep 12;3:952233. doi: 10.3389/falgy.2022.952233

Figure 2.

Figure 2

Therapeutic targeting of pathways in HAE. Inhibitors of the pathway are shown in light gray shaded boxes at their respective sites of action. Investigational therapies are shown with dashed lines at their target sites. C1-INH, C1 esterase inhibitor; HMW, high molecular weight; pdC1-INH, plasma-derived C1-INH; rhC1-INH, recombinant human C1-INH. Figure created with data from Cicardi M, et al. J Allergy Clin Immunol Pract. (2018) 6(4):1132–41; Zuraw BL. N Engl J Med. (2008) 359(10):1027–36; and Fijen LM, et al. Clin Rev Allergy Immunol. (2021) 61(1):66–7 (5, 14, 16).